General Information of the Drug (ID: M6APDG03927)
Name
MMI-0100
Synonyms
Peptide MAPKAPK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix; Peptide MK2 inhibitors (inflammation/scarring/fibrosis), Moerae Matrix
    Click to Show/Hide
Status
Phase 1
TTD Drug ID
D0S7NS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
MAPK-activated protein kinase 2 (MAPKAPK2)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary MAPK-activated protein kinase 2 (MAPKAPK2) is a therapeutic target for MMI-0100. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of MMI-0100 through regulating the expression of MAPK-activated protein kinase 2 (MAPKAPK2). [1], [2]
References
Ref 1 The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018 Feb;52(2):621-629. doi: 10.3892/ijo.2017.4219. Epub 2017 Dec 7.
Ref 2 National Cancer Institute Drug Dictionary (drug id 577812).